论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
手术、化疗联合辛替单抗治疗原发性中枢神经系统结外 NK/T 细胞淋巴瘤:一病例报告和文献综述
Authors Qin L, Li Y, He Y, Zeng R, Pan T, Zuo Y, Xiao L, Zhou H
Received 8 October 2021
Accepted for publication 20 December 2021
Published 6 January 2022 Volume 2022:15 Pages 1—11
DOI https://doi.org/10.2147/OTT.S343400
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
Abstract: Primary central nervous system extranodal natural killer/T-cell lymphoma (PCNS ENK/TCL) is an extremely rare lymphoma. Only 23 cases of PCNS ENK/TCL have been reported in the English literature. Due to the rarity of this lymphoma, an effective therapeutic strategy has not been defined. Generally, this type of lymphoma is treated with surgery, intrathecal chemotherapy, and postoperative chemoradiation therapy. The prognosis is poor. Herein, we present a case of primary brain NK/T cell lymphoma in a 50-year-old immunocompetent Chinese female and review the literature. The patient underwent intracranial tumor resection and was subsequently treated with a PD1 monoclonal antibody (Sintilimab) combined with chemotherapy. The patient survived 15 months after diagnosis. This is the first report of PCNS ENK/TCL treated with surgery and chemotherapy combined with immunotherapy and suggests an effective treatment regimen for PCNS ENK/TCL.
Keywords: primary central nervous system, extranodal natural killer/T-cell lymphoma, chemotherapy, immunotherapy, PD1